Venetoclax in Higher-Risk MDS/AML

preview_player
Показать описание
Dr. Götze will explore the potential of venetoclax in the treatment of higher-risk MDS.
  1. MDS Foundation, Inc.
Рекомендации по теме
Venetoclax in Higher-Risk 0:16:23

Venetoclax in Higher-Risk MDS/AML

Venetoclax with decitabine 0:02:05

Venetoclax with decitabine for high-risk AML and MDS

Jacqueline Garcia: Evaluating 0:06:53

Jacqueline Garcia: Evaluating Venetoclax Plus Azacitidine in Patients with High-Risk MDS

Venetoclax plus azacitidine 0:08:54

Venetoclax plus azacitidine in treatment-naïve higher-risk MDS

Venetoclax plus azacitidine 0:06:58

Venetoclax plus azacitidine for higher-risk MDS

Venetoclax and magrolimab 0:02:53

Venetoclax and magrolimab for treatment of AML and MDS

Dose modification strategies 0:02:42

Dose modification strategies in high-risk MDS treated with venetoclax and azacitidine

Expert Video Report 0:06:53

Expert Video Report on Acute Myeloid Leukemia and high risk MDS from ASH 2020

Azacitidine and Venetoclax 0:03:36

Azacitidine and Venetoclax for High-risk #MDS Patients | Jacqueline S. Garcia, MD | ASH 2023

Venetoclax plus azacitidine 0:03:51

Venetoclax plus azacitidine in treatment-naïve and R/R MDS

Understanding Higher Risk 1:13:29

Understanding Higher Risk MDS and Transtion to AML

Phase III VERONA 0:03:07

Phase III VERONA study of venetoclax with azacitidine in treatment-naïve higher-risk MDS

How could venetoclax 0:08:06

How could venetoclax combinations improve outcome in high-risk MDS?

Venetoclax and azacitidine 0:05:36

Venetoclax and azacitidine in MDS patients

Rationale for 10-day 0:02:16

Rationale for 10-day decitabine with venetoclax for high-risk AML

Higher-risk MDS and 0:33:29

Higher-risk MDS and AML: How new guidelines are changing diagnosis, classification and management

ASTX727 plus venetoclax: 0:04:10

ASTX727 plus venetoclax: Phase I study of total oral therapy for high-risk MDS/CMML

Venetoclax and 5-azacytidine 0:03:03

Venetoclax and 5-azacytidine for the treatment of MDS and CMML

Real-world data on 0:02:21

Real-world data on venetoclax-based regimens for patients with AML or MDS with excess blasts-2

Community Perspectives on 1:32:49

Community Perspectives on Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndrome

Venetoclax with azacitidine 0:03:17

Venetoclax with azacitidine in HR-MDS

CPX-351 plus venetoclax 0:02:11

CPX-351 plus venetoclax in patients with newly-diagnosed high-risk AML

Higher-risk MDS and 0:57:07

Higher-risk MDS and newly diagnosed AML: What are the latest developments from EHA 2022?

Optimal Use of 0:03:12

Optimal Use of Venetoclax in AML